Viewing Study NCT02551159


Ignite Creation Date: 2025-12-24 @ 2:34 PM
Ignite Modification Date: 2026-02-22 @ 7:23 PM
Study NCT ID: NCT02551159
Status: COMPLETED
Last Update Posted: 2021-10-13
First Post: 2015-09-09
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Phase III Open Label Study of MEDI 4736 With/Without Tremelimumab Versus Standard of Care (SOC) in Recurrent/Metastatic Head and Neck Cancer
Sponsor: AstraZeneca
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Squamous Cell Carcinoma of the Head and Neck View
Keywords:

Keywords

Keyword Brief Keyword Text View
None programmed cell death ligand 1 (PD-L1), MEDI4736, Cytotoxic T-lymphocyte-associated antigen … View